Regenerative Medical Technology Group AI Stock Analysis
Want to see RMTG full AI Analyst Report?
Regenerative Medical Technology Group (RMTG) AI Stock Analysis
Regenerative Medical Technology Group
(Other OTC:RMTG)
The score is primarily constrained by high financial risk (negative equity, sizable debt relative to assets, ongoing net losses and negative free cash flow) and weak technical momentum (trading below key moving averages with negative MACD and very low RSI). Strong revenue growth and positive corporate messaging around scaling and deleveraging provide some support, but not enough to offset balance-sheet strain and downtrend signals.
Regenerative Medical Technology Group (RMTG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $412.17K
- Dividend Yield
- ―
- Average Volume (3M)
- 57.52K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -1.53
- Revenue Growth
- 94.32%
- EPS Growth
- -158.38%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Regenerative Medical Technology Group Business Overview & Revenue Model
Company Description
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of st...
Regenerative Medical Technology Group Financial Statement Overview
Summary
Revenue growth is strong (TTM up ~47.7%) with solid gross margin (~59.8%) and improved operating results (small positive EBIT). However, the company remains deeply unprofitable (TTM net margin around -101%), has negative equity (about -$39.3M) alongside sizeable debt (~$21.7M) versus a small asset base, and free cash flow is still negative—together indicating elevated financial and funding risk.
Income Statement
34NegativeBalance Sheet
18Very NegativeCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.41M | 5.10M | 4.11M | 2.41M | 1.53M | 437.89K |
| Gross Profit | 5.51M | 2.81M | 2.82M | 1.68M | 876.97K | 150.14K |
| EBITDA | 2.00M | -83.56K | 301.74K | -3.01M | -1.02M | -10.11M |
| Net Income | -9.53M | -7.81M | -5.56M | -9.81M | -5.49M | -12.88M |
Balance Sheet | ||||||
| Total Assets | 5.85M | 4.49M | 3.82M | 2.88M | 8.08M | 9.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.32M | 956.72K | 1.17M | 530.54K | 1.65M | 2.98M |
| Total Debt | 21.74M | 19.57M | 20.05M | 17.65M | 15.14M | 13.37M |
| Total Liabilities | 45.11M | 39.23M | 31.18M | 24.67M | 20.06M | 16.06M |
| Stockholders Equity | -39.26M | -34.75M | -27.36M | -21.80M | -11.98M | -6.76M |
Cash Flow | ||||||
| Free Cash Flow | -582.33K | -1.31M | 635.28K | -804.80K | -1.31M | -9.88M |
| Operating Cash Flow | 268.56K | -706.52K | 850.70K | -419.20K | -1.11M | -9.88M |
| Investing Cash Flow | -850.89K | -602.58K | -215.42K | -385.60K | -198.43K | 666.47K |
| Financing Cash Flow | 291.38K | 1.10M | 0 | -309.85K | -20.78K | 12.15M |
Regenerative Medical Technology Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RMTG, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 25.28 is Positive, neither overbought nor oversold. The STOCH value of 30.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RMTG.
Regenerative Medical Technology Group Risk Analysis
Regenerative Medical Technology Group disclosed 37 risk factors in its most recent earnings report. Regenerative Medical Technology Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRegenerative Medical Technology Group Peers Comparison
Overall Rating
BJDX44Neutral
WOK43Neutral
RMTG43Neutral
IVF42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $2.92M | -0.11 | -113.80% | ― | ― | 95.46% | |
| 43Neutral | $5.36M | -0.01 | -18.55% | ― | ― | ― | |
| 43Neutral | $412.17K | -0.04 | 27.29% | ― | 94.32% | -158.38% | |
| 42Neutral | $3.10M | -0.02 | -47.41% | ― | 13.76% | 99.18% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RMTG | Regenerative Medical Technology Group Inc. | 0.03 | -0.03 | -49.15% | |
| BBLG | Bone Biologics Corp | 0.33 | -1.30 | -80.06% | |
| IVF | Invo Fertility Inc | 2.60 | -70.68 | -96.45% | |
| BJDX | Bluejay Diagnostics, Inc. | 2.61 | -20.27 | -88.59% | |
| NIVF | Newgenivf Group Limited | 0.23 | -6073.69 | -100.00% | |
| WOK | WORK Medical Technology Group LTD | 1.20 | -40898.80 | -100.00% |
Regenerative Medical Technology Group Corporate Events
Regenerative Medical Technology Group Highlights Growth, Financing Strategy
PositiveOn August 20, 2026, Regenerative Medical Technology Group held a previously announced investor video call in which management addressed shareholder questions about growth, financing, and strategic direction. Executives highlighted strong revenue mome...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
